As we move through 2025, the scientific frontier in Japan is shifting from symptomatic relief toward disease-modifying therapies that target the root genetic cause of Dravet Syndrome. Investigational gene regulation therapies, such as antisense oligonucleotides (ASOs), are designed to upregulate the expression of the healthy SCN1A gene, potentially restoring the necessary levels of sodium...